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Abstract
Background Mutations in the myosin heavy chain 7
(MYH7) gene commonly cause cardiomyopathy but are
less frequently associated with congenital heart defects.
Methods In this study, we describe a mutation in the
MYH7 gene, c. 5754C > G; p. (Asn1918Lys), present in
15 probands and 65 family members.
Results Of the 80 carriers (age range 0–88 years), 46
(57.5%) had cardiomyopathy (mainly dilated cardiomyopa-
thy (DCM)) and seven (8.8%) had a congenital heart defect.
Childhood onset of cardiomyopathy was present in almost
10% of carriers. However, in only a slight majority (53.7%)
was the left ventricular ejection fraction reduced and almost
no arrhythmias or conduction disorders were noted. More-
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over, only one carrier required heart transplantation and
nine (11.3%) an implantable cardioverter defibrillator. In
addition, the standardised mortality ratio for MYH7 carriers
was not significantly increased. Whole exome sequencing
in several cases with paediatric onset of DCM and one with
isolated congenital heart defects did not reveal additional
known disease-causing variants. Haplotype analysis sug-
gests that the MYH7 variant is a founder mutation, and is
therefore the first Dutch founder mutation identified in the
MYH7 gene. The mutation appears to have originated in the
western region of the province of South Holland between
500 and 900 years ago.
Conclusion Clinically, the p. (Asn1918Lys) mutation is
associated with congenital heart defects and/or cardiomy-
opathy at young age but with a relatively benign course.
Keywords Founder mutation · Cardiomyopathy ·
Congenital heart defect · Beta myosin heavy chain 7
Introduction
The myosin heavy chain 7 (MYH7) gene (OMIM, #160760)
encodes a sarcomere protein. Mutations in MYH7 are
a well-known cause of several types of cardiomyopathy,
including hypertrophic cardiomyopathy (HCM) [1], dilated
cardiomyopathy (DCM) [2], possibly occurring as peri-
partum cardiomyopathy [3], and left ventricular noncom-
paction, also referred to as noncompaction cardiomyopathy
(NCCM) [4], in addition to skeletal myopathies with or
without cardiac involvement [5]. Furthermore, several mu-
tations in MYH7 have been associated with congenital
heart defects (CHDs), including Ebstein’s anomaly [6],
bicuspid aortic valve (BAV) [7], and ventricular septal
















































Fig. 1 Histograms showing the percentage of carriers with cardiomyopathy by age of onset of cardiomyopathy (in 20-year categories): a per type
of cardiomyopathy: DCM (light upward diagonal lines), NCCM (black). The only carrier with HCM is excluded; and (b) per gender: female (light
upward diagonal lines), male (black)
defect (VSD) [8], but thus far always in combination with
cardiomyopathy (typically NCCM).
Several known pathogenic mutations in the MYH7 gene
are founder mutations, mutations that show a high fre-
quency in a specific culturally or geographically isolated
population. MYH7 founder mutations have been described
in South Africa [9], Finland [10], and Spain [11]. To the
best of our knowledge, no Dutch MYH7 founder mutation
has been reported to date.
We now describe a founder mutation in MYH7, c. 5754C>
G; p. (Asn1918Lys), which is associated with several forms
of cardiomyopathy with early or even prenatal onset in
some patients, and with CHDs without cardiomyopathy
even at advanced age.
Methods
Clinical evaluation
Clinical data were retrospectively collected on 15 probands
(the first diagnosed case in a family) (A–O; family H was
published previously [6]) and 65 of their family members,
all of whom carried the MYH7 p. (Asn1918Lys) mutation.
All carriers were counselled at one of three academic cen-
tres (Leiden University Medical Centre, Erasmus Medical
Centre Rotterdam or Academic Medical Centre Amster-
dam).
Clinical information consisted of a medical and fam-
ily history, physical examination, 12-lead electrocardiogram
(ECG), echocardiography, exercise test and 24-hour (or 48-
hour) Holter monitoring. If available, cardiac magnetic res-
onance imaging was also assessed. The cardiac phenotype
was defined as either meeting criteria for a cardiomyopa-
thy (defined as myocardial disease characterised by struc-
turally and functionally abnormal myocardium and absence
of other diseases, including congenital heart disease, suffi-
cient to cause the observed myocardial abnormality) [12],
and/or presence of a (corrected) CHD. Written informed
consent was obtained from all participants as approved by
local medical ethics committees.
Genetic evaluation
Genomic DNA was extracted from peripheral blood sam-
ples using standard procedures. Probands were analysed
between 2005 and 2016, initially by Sanger sequencing
and then by next-generation sequencing using targeted
gene panels [13]. Genetic variants were evaluated for their
potential pathogenicity using in silico prediction tools, as
available via the Alamut software (Interactive Biosoftware,
Rouen, France).
Haplotype analysis was performed using 16 microsatel-
lite markers around MYH7. DNA from 14 probands was
analysed, and DNA samples of 6 family members carrying
the mutation were used to verify the phase and reconstruct
the haplotype. The age of the haplotype was based on the es-
timated number of generations since the mutation occurred
[14], assuming 20–25 years per generation.
A Cytoscan HD SNP array (Affymetrix, Santa Clara,
CA, USA) was performed on DNA from a carrier with
a CHD (BAV) but without cardiomyopathy. DNA from this
individual and three other carriers with childhood onset car-
diomyopathy, and their parents, was used for whole exome
sequencing (mean coverage ~100x). In brief, the exome was
enriched with the Agilent Sureselect XT Human All Exon
V5 kit followed by Illumina Hiseq2500 sequencing. The ex-
ome sequence was analysed using a stringent post-sequenc-
ing annotation pipeline (BWA-GATK-VEP) [15, 16]. Vari-
ant filtering and interpretation using a gene panel for CHDs
of 81 genes (list available upon request: ldga@lumc.nl; in-
cluding the NOTCH1 gene, known to be associated with
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Table 1 Clinical characteristics of the MYH7 p. (Asn1918Lys) muta-
tion carriers
Probands Family members
Clinical diagnosis (15) (65)
– CMP 15 (100%) 31 (47.7%)
– CHD 1 (6.7%) 6 (9.2%)
Clinical measures (14) (27)
– LVEF
 <60% 5 (35.7%) 17 (63.0%)
 <40% 8 (57.1%) 5 (18.5%)
– Arrhythmia/
conduction
 (P)AF 0 (0%) 2 (7.4%)
 Total AV block 0 (0%) 1 (3.7%)
 VT/VF 1 (7.1%) 0 (0%)
Outcome measures (15) (65)
– ICD implantation 6 (40%) 3 (9.6%)a
– Heart transplanta-
tion
0 (0%) 1 (3.2%)
– Death 0 (0%) 1 (3.2%)
n number of carriers with available clinical data, CMP cardiomy-
opathy, CHD congenital heart disease, LVEF left ventricular ejection
fraction, (P)AF (paroxysmal) atrial fibrillation, AV atrioventricular,
VT/VF ventricular tachycardia/ventricular fibrillation, ICD implantable
cardioverter defibrillator
aCarrier with DDD-R pacemaker excluded
BAV) was performed on the exome data of the first carrier
using a custom-made version of the Leiden Open Varia-
tion Database (LOVDplus). For three childhood onset car-
riers, data files were uploaded to Cartagenia NGS bench
(Cartagenia, Leuven, Belgium) and filtered using an auto-
mated filter tree. First, variants present in ~2,700 genes in-
cluded in the Agilent SureSelect Inherited Disease (SSID)
panel were selected. Next, variants in genes listed under
the human phenotype ontology (HPO) term cardiomyopa-
thy (HP:0001638; http://www.human-phenotype-ontology.
org/) were selected, supplemented by genes absent from
this HPO but otherwise associated with cardiomyopathy
[17]. Interpretation was based on in-house lists available at
the University Medical Centre Groningen, frequencies in
population databases (ExAC, GoNL), in silico prediction
programs (Alamut) and literature. Variants were reported
as described (http://varnomen.hgvs.org/).
Pedigree evaluation
Family pedigrees were constructed to determine presence
or absence of the phenotype in mutation carriers and non-
carriers (co-segregation). State archives, civil registers and
online web trees from the west of the Netherlands were used
to identify common ancestors. Postal codes of all carriers
were plotted to determine the geographical distribution of
the MYH7 mutation.
Statistical analysis
Descriptive statistics and the Mann-Whitney U test for me-
dian age of onset of cardiomyopathy (with interquartile
range, IQR) per gender and per type of cardiomyopathy
were performed using SPSS software (version 23.0, IBM
Corp., Armonk, NY, USA). The standardised mortality ra-
tio for MYH7 carriers was estimated by utilising the mortal-
ity rate in the Dutch population in 2005 (https://www.cbs.
nl/nl-nl/cijfers#theme=bevolking). Point estimate and cor-
responding 95% confidence intervals were calculated us-
ing Stata (StataCorp. 2015. Stata Statistical Software: Re-
lease 14. College Station, TX: StataCorp LP). Values of p <
0.05 were considered significant.
Results
Demographic data and risk factors
Of the 80 MYH7 mutation carriers, 35 (44%) were male and
the median age at testing was 47 years (IQR: 29.25–61).
There were no significant differences in cardiovascular risk
factors (hypertension, hypercholesterolaemia, diabetes and
smoking) between carriers with a phenotype (either car-
diomyopathy and/or CHDs, n = 49) and those without (n =
31). Two (6.5%) of the 31 carriers without a phenotype had
symptoms of angina at the time of testing, one of whom
was treated with percutaneous coronary intervention.
Clinical diagnosis
Cardiomyopathy. Of the 15 probands, 9 met criteria for
DCM, 5 for NCCM and 1 for HCM. Of the 65 family
members, 31 were diagnosed with a cardiomyopathy, in-
cluding 23 with DCM and 8 with NCCM, giving an overall
penetrance for cardiomyopathy among the mutation carri-
ers of 47.7%. Although eight family members were diag-
nosed with cardiomyopathy before the age of 12, overall
median age of onset was 39 years (IQR: 25–56.5). There
were no differences in age of onset per type of cardiomy-
opathy (40 years with IQR: 24.5–58 for DCM versus 30.5
years with IQR: 23.3–46.8 for NCCM, p = 0.38; the carrier
with HCM was excluded, see Fig. 1a) nor per gender (32.5
years with IQR:7.25–54.25 for men versus 39 years with
IQR:27–59 for women, p = 0.27; see Fig. 1b). In the female
age group 20–39 years, 4 out of 10 had signs of peripartum
cardiomyopathy.
Congenital heart defects. Seven of 80 (8.8%) MYH7 mu-
tation carriers showed CHDs, including BAV (n = 4), BAV
with coarctation of the aorta (n = 1), VSD (n = 1), and Eb-
stein’s anomaly (n = 1). In addition, two family members
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Fig. 2 Postal code map. Number of carriers per postal code. Between
brackets the number of postal code areas containing that specific num-
ber of carriers
not tested for the mutation but with a 50% risk of being
a carrier also had BAV (see individuals with (+), family D
in Fig. 3). CHDs were confined to four of the 15 families
(families A, C, D, and H in Fig. 3). The status of the aortic
valve was not mentioned in the echocardiographic report
of 12 MYH7 mutation carriers. Three carriers with BAV
showed no cardiomyopathy, even though the youngest was
57 years of age. A cytoscan in one of these patients (see
individual with (), family D in Fig. 3) revealed no copy
number changes and exome sequencing data showed no
other mutation that might explain the CHD.
Clinical characteristics
Over half of all probands (57.1%) showed a moderate to
severely reduced left ventricular ejection fraction (LVEF,
see Tab. 1), whereas the majority of family members with
cardiomyopathy (63%) had mild to moderately reduced
LVEF. Almost no arrhythmias or conduction disorders have
been noted since the time of original testing. Six probands
and three family members received an implantable car-
dioverter defibrillator (ICD). Of the six cases with avail-
able ICD records, only one had documented appropriate
shock. One male family member underwent a heart trans-
plant at age 50 and one female family member died at the
age of 89 from heart failure, which was most likely due to
ischaemia. The standardised mortality ratio was 1.19 (CI
95%: 0.74–1.80).
Genetic diagnosis
The c. 5754C > G; p. (Asn1918Lys) variant in exon 39 of
MYH7 (reference sequence NM_000257.3) was identified
by Sanger or next-generation sequencing, and subsequently
confirmed in the proband and family members by Sanger
sequencing. The Asn1918 residue shows strong conserva-
tion between species, and the variant is located at the end
of an important functional protein domain (coiled coil rod
region). In addition, the variant was not identified in 170
ethnically-matched controls. However, as asparagine and
lysine show no major differences in physicochemical prop-
erties (Grantham score: 94 [0–215]) the variant was initially
classified as ‘likely pathogenic’, and was only reclassified
as pathogenic following a report by Postma et al. in 2011
[5]. The variant is currently absent from >60,000 control
exomes (ExAC database) (http://exac.broadinstitute.org).
Geographical and historical origin of the mutation
Geographical distribution. Analysis of carrier postal
codes (Fig. 2) showed that the mutation occurs mainly in
the western part of the province of South-Holland. Despite
this endemic location, no bi-allelic mutation carrier was
encountered.
Genealogy. Genealogical research identified three pedi-
grees going back 11 generations (Fig. 3, families A, B
and C) that were linked by a common ancestor around the
mid-17th century.
Haplotype analysis. A shared haplotype of at least two
markers was found covering an 800 kb region surrounding
MYH7 (see Table 1 of the online Electronic Supplementary
Material (ESM)). Based on haplotype data, we estimated
that the MYH7 mutation arose 25–36 generations ago and is
500–900 years old (assuming 20–25 years per generation).
Genetic variability
Probands. DNA variants in other genes (all classified
as variants of unknown significance) were found in five
probands tested in accordance with current practice in the
Netherlands (core set of at least 45 genes). None of these
DNA variants was shared (Online ESM Table 2, upper part).
Family members. Exome sequencing in three family
members (see individuals with (), family B in Fig. 3) with
an early age of onset (respectively prenatally, at the age of 1
and 7 years) found DNA variants of unknown significance
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Fig. 3 Pedigrees A through J (families of probands K–O are not shown as no family members are tested). Partly or fully filled symbols represent
affected individuals (see box for explanation); (open symbols unaffected individuals, diagonal line deceased, arrow proband, + MYH7 mutation
carrier, + 50% risk for MYH7 mutation,  tested with exome sequencing)
in two cases. No variant was shared (Online ESM Table 2,
lower part).
Discussion
In this report, we identified 80 carriers of an MYH7 founder
mutation. Phenotypically, the MYH7 p. (Asn1918Lys) mu-
tation appears to be more closely associated with DCM,
possibly as peripartum cardiomyopathy, or NCCM than
HCM, as seen with other mutations in the tail region of
the MYH7 gene [18]. MYH7 mutations have occasionally
been described in children with HCM [19] and with DCM
[20], and even prenatally for DCM [21] or NCCM [22, 23].
However, an almost 10% prenatal or early childhood onset
(<12 years) cardiomyopathy was unexpected. Interestingly,
and despite the young age of onset of cardiomyopathy, this
MYH7 mutation appears to result in only mild to moderate
clinical symptoms.
From a developmental point of view, the currently re-
ported CHD (Ebstein’s anomaly, VSD, coarctation of the
aorta and BAV) are all related to epicardial deficiencies
[24] and, especially coarctation of the aorta, but also VSD
and Ebstein’s anomaly, are known to be associated with
BAV [25]. Although previous reports have described these
CHDs in patients with specific MYH7 mutations [4, 6–8,
26, 27] residing in the head and rod domain of the gene,
p. (Asn1918Lys) is the only CHD-associated mutation that
affects the tail region of the gene. Moreover, all previously
described patients with an MYH7 mutation and a CHD also
had cardiomyopathy. The p. (Asn1918Lys) mutation is cur-
rently associated with CHDs in the absence of cardiomy-
opathy, although we cannot exclude that cardiomyopathy
may develop later in life (>57 years).
The overall prevalence of CHDs in our cohort (8.8%)
was higher than in the general population (1%) and was
mainly explained by BAV (at least 6.3% in our patients
versus 1.4% in the general population) [28]. Common epi-
cardial deficiencies during development [24] might explain
currently found CHDs in carriers of this MYH7 mutation.
However, as the CHDs were limited to four of the 15 fami-
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lies, other genetic or common environmental factors might
be involved.
In families with inherited cardiomyopathies, DNA test-
ing or regular cardiology examinations are advised from
age 10 onwards. Based on current data, cardiac screening
or genetic testing can be envisaged at an earlier age in chil-
dren of a p. (Asn1918Lys) mutation carrier. In addition,
at-risk couples should be advised of the need for prenatal
echocardiography to detect CHDs. Furthermore, both our
and other studies [29, 30] suggest a possible role for the
MYH7 gene and other sarcomere genes (i. e. MYH6) in the
development of CHDs. Inclusion of the MYH7 gene (and
possibly other sarcomere genes) in current gene panels for
CHDs should now be considered.
Our study design had several limitations. First, the retro-
spective design meant that follow-up data were not available
for carriers under control elsewhere. Second, the follow-up
period was limited to 11 years. Longer follow-up may im-
prove cardiomyopathy penetrance estimates, especially in
current CHD-only cases. Third, the numbers are too small
for reliable estimation of the prevalence of CHD associated
with this MYH7 mutation. Finally, due to limitations in the
genetic analysis of probands and family members, a role
for other genes cannot be excluded.
In conclusion, this study describes the first Dutch
founder mutation in the MYH7 gene, a mutation asso-
ciated with CHDs and cardiomyopathies, with frequent
childhood onset but a relatively benign course.
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